Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Elisa A. Rozeman; Alexander M. Menzies; Alexander C. J. van Akkooi; Chandra Mani Adhikari; Carolien Bierman; Bart A. van de Wiel; Richard A. Scolyer; Oscar Krijgsman; Karolina Sikorska; Hanna Eriksson; Annegien Broeks; Johannes V. van Thienen; Alexander Guminski; Alex Torres Acosta; Sylvia ter Meulen; Anne Miek Koenen; Linda J.W. Bosch; Kerwin F. Shannon; Loes M. Pronk; Maria Gonzalez; Sydney Ch’ng; Lindsay G. Grijpink-Ongering; Jonathan R. Stretch; Stijn W. T. P. J. Heijmink; Harm van Tinteren; John B.A.G. Haanen; Omgo E. Nieweg; W. Martin C. Klop; Charlotte L. Zuur; Robyn P.M. Saw; Winan J. van Houdt; Daniel S. Peeper; Andrew J. Spillane; Johan Hansson; Ton N. Schumacher; Georgina V. Long; Christian U. Blank

doi:10.1016/s1470-2045(19)30151-2

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Elisa A. Rozeman(The Netherlands Cancer Institute), Alexander M. Menzies(The University of Sydney), Alexander C. J. van Akkooi(The Netherlands Cancer Institute), Chandra Mani Adhikari(The University of Sydney), Carolien Bierman(The Netherlands Cancer Institute), Bart A. van de Wiel(The Netherlands Cancer Institute), Richard A. Scolyer(The University of Sydney), Oscar Krijgsman(The Netherlands Cancer Institute), Karolina Sikorska(The Netherlands Cancer Institute), Hanna Eriksson(Karolinska University Hospital), Annegien Broeks(The Netherlands Cancer Institute), Johannes V. van Thienen(The Netherlands Cancer Institute), Alexander Guminski(The University of Sydney), Alex Torres Acosta(The Netherlands Cancer Institute), Sylvia ter Meulen(The Netherlands Cancer Institute), Anne Miek Koenen(The Netherlands Cancer Institute), Linda J.W. Bosch(The Netherlands Cancer Institute), Kerwin F. Shannon(The University of Sydney), Loes M. Pronk(The Netherlands Cancer Institute), Maria Gonzalez(The University of Sydney), Sydney Ch’ng(The University of Sydney), Lindsay G. Grijpink-Ongering(The Netherlands Cancer Institute), Jonathan R. Stretch(The University of Sydney), Stijn W. T. P. J. Heijmink(The Netherlands Cancer Institute), Harm van Tinteren(The Netherlands Cancer Institute), John B.A.G. Haanen(The Netherlands Cancer Institute), Omgo E. Nieweg(The University of Sydney), W. Martin C. Klop(The Netherlands Cancer Institute), Charlotte L. Zuur(The Netherlands Cancer Institute), Robyn P.M. Saw(The University of Sydney), Winan J. van Houdt(The Netherlands Cancer Institute), Daniel S. Peeper(The Netherlands Cancer Institute), Andrew J. Spillane(The University of Sydney), Johan Hansson(Karolinska University Hospital), Ton N. Schumacher(The Netherlands Cancer Institute), Georgina V. Long(The University of Sydney), Christian U. Blank(The Netherlands Cancer Institute)

The Lancet Oncology

May 31, 2019

10.1016/s1470-2045(19)30151-2

Cited by 519

Abstract

Related Papers

No related papers found

Powered by citation graph analysis